AI English summary of an SEC filing — figures as filed
Eli Lilly LLYEli Lilly said revenue in 2024 increased driven by increased volume and, to a lesser extent, higher realized prices. The company cited Mounjaro, Zepbound, and Verzenio as drivers of the revenue increase, with Trulicity partially offsetting the growth.
Key points
AI summaryEli Lilly said revenue in 2024 increased driven by increased volume and, to a lesser extent, higher realized prices. The company cited Mounjaro, Zepbound, and Verzenio as drivers of the revenue increase, with Trulicity partially offsetting the growth.
Eli Lilly said net income and diluted earnings per share increased in 2024, primarily due to higher gross margin, partially offset by increased research and development expenses, marketing, selling, and administrative expenses, and asset impairment, restructuring, and other special charges.
Eli Lilly said Mounjaro revenue in the U.S. increased 85%, while revenue outside the U.S. was $2.59 billion in 2024 compared to $328.9 million in 2023. Trulicity revenue in the U.S. decreased 32%, and revenue outside the U.S. decreased 8%.
Eli Lilly said in August 2024 HHS announced government-set prices for Jardiance at a 66% discount compared to the 2023 U.S. calendar year list price for a 30-day supply, effective in 2026. The company said it expects additional significant products will be selected in future years.
Key figures
Fiscal year ended December 31, 2024
- Revenue
- $45.0B
- Net income
- $10.6B
- EPS
- $11.71
- Operating cash flow
- $8.8B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
2024 Revenue Growth Drivers
Eli Lilly said revenue in 2024 increased driven by increased volume and, to a lesser extent, higher realized prices. The company cited Mounjaro, Zepbound, and Verzenio as drivers of the revenue increase, with Trulicity partially offsetting the growth.
Source · Based on the MD&A text of the filing
Net Income and Earnings Per Share Changes
Eli Lilly said net income and diluted earnings per share increased in 2024, primarily due to higher gross margin, partially offset by increased research and development expenses, marketing, selling, and administrative expenses, and asset impairment, restructuring, and other special charges.
Source · Based on the MD&A text of the filing
Mounjaro and Trulicity Revenue Changes
Eli Lilly said Mounjaro revenue in the U.S. increased 85%, while revenue outside the U.S. was $2.59 billion in 2024 compared to $328.9 million in 2023. Trulicity revenue in the U.S. decreased 32%, and revenue outside the U.S. decreased 8%.
Source · Based on the MD&A text of the filing
Jardiance Government Price Setting Under the IRA
Eli Lilly said in August 2024 HHS announced government-set prices for Jardiance at a 66% discount compared to the 2023 U.S. calendar year list price for a 30-day supply, effective in 2026. The company said it expects additional significant products will be selected in future years.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…